Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 19;7:11610. doi: 10.1038/ncomms11610

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Human basophils from three healthy volunteers were isolated, stripped of native IgE by bi53_79 DARPin treatment and reloaded with NP-reactive JW8-IgE. These NP-reactive basophils were then cultured with or without omalizumab and IgE-R419N-Fc_3-4 as indicated for 3 (a) or 6 (b) days before antigen challenge. Basophil activation was assessed by the per cent of CD63-positive cells. There was a statistically significant difference between groups as determined by a repeated-measures analysis of variance (F=7.4, P=0.0004 Day 3 and F=19.3, P=0.0001 Day 6), and a Tukey post hoc test was used to determine the significance of differences between groups. On day 6, the untreated basophils showed reduced activation, which likely reflects the spontaneous loss of IgE.